参考文献/References:
[1] 高润霖. 中国心瓣膜病现状[J]. 华西医学,2018,33(2):127-131.
[2] Smith CRLeon MB,Mack MJ,et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients[J]. N Engl J Med,2011,364(23):2187-2198.
[3] Otto CM,Nishimura RA,Bonow RO,et al. 2020 ACC/AHA Guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation,2021,143(5):e72-72e227.
[4] Leon MB,Smith CR,Mack MJ,et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients[J]. N Engl J Med,2016,374(17):1609-1620.
[5] Mack MJ,Leon MB,Thourani VH,et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients[J]. N Engl J Med,2019,380(18):1695-1705.
[6] Chugh SS,Havmoeller R,Narayanan K,et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study[J]. Circulation,2014,129(8):837-847.
[7] Okuno T,Hagemeyer D,Brugger N,et al. Valvular and nonvalvular atrial?fibrillation in patients undergoing transcatheter aortic valve replacement[J]. JACC Cardiovasc Interv,2020,13(18):2124-2133.
[8] Ten Berg J,Sibbing D,Rocca B,et al. Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI),in collaboration with the ESC Council on Valvular Heart Disease[J]. Eur Heart J,2021,42(23):2265-2269.
[9] Mentias A,Saad M,Girotra S,et al. Impact of pre-existing and new-onset?atrial?fibrillation on outcomes after transcatheter aortic?valve replacement[J]. JACC Cardiovasc Interv,2019,12(21):2119-2129.
[10] J?rgensen TH,Thygesen JB,Thyregod HG,et al. New-onset atrial fibrillation after surgical aortic valve replacement and transcatheter aortic valve implantation:a concise review[J]. J Invasive Cardiol,2015,27(1):41-47.
[11] Biviano AB,Nazif T,Dizon J,et al. Atrial fibrillation is associated with increased mortality in patients undergoing transcatheter aortic valve replacement: insights from the placement of aortic transcatheter valve (PARTNER) trial[J]. Circ Cardiovasc Interv,2016,9(1):e002766.
[12] Doshi R,Pisipati S,Taha M,et al. Incidence,30-day readmission rates and predictors of readmission after new onset atrial fibrillation who underwent transcatheter aortic valve replacement[J]. Heart Lung,2020,49(2):186-192.
[13] Vora AN,Dai D,Matsuoka R,et al. Incidence,management,and associated clinical outcomes of new-onset atrial fibrillation following transcatheter aortic valve replacement: an analysis from the STS/ACC TVT registry[J]. JACC Cardiovasc Interv,2018,11(17):1746-1756.
[14] Tarantini G,Mojoli M,Windecker S,et al. Prevalence and impact of atrial fibrillation in patients with severe aortic stenosis undergoing transcatheter aortic valve?replacement:an analysis from the SOURCE XT prospective multicenter?registry[J]. JACC Cardiovasc Interv,2016,9(9):937-946.
[15] Shaul AA,Kornowski R,Bental T,et al. Type of atrial fibrillation and clinical outcomes in patients undergoing transcatheter aortic valve replacement[J]. Ann Noninvasive Electrocardiol,2016,21(5):519-525.
[16] Sepehri Shamloo A,Dagres N,Hindricks G.2020 ESC guidelines on atrial fibrillation:summary of the most relevant recommendations and innovations[J]. Herz,2021,46(1):28-37.
[17] Wu VC,Wu M,Aboyans V,et al. Female sex as a risk factor for ischaemic stroke varies with age in patients with atrial fibrillation[J]. Heart,2020,106(7):534-540.
[18] Tomasdottir M,Friberg L,Hijazi Z,et al. Risk of ischemic stroke and utility of CHA(2)DS(2)-VASc score in women and men with atrial fibrillation[J]. Clin Cardiol,2019,42(10):1003-1009.
[19] Chang G,Xie Q,Ma L,et al. Accuracy of HAS-BLED and other bleeding risk assessment tools in predicting major bleeding events in atrial fibrillation:a network meta-analysis[J]. J Thromb Haemost,2020,18(4):791-801.
[20] 中国医师协会心血管内科医师分会结构性心脏病专业委员会. 经导管主动脉瓣置换术中国专家共识(2020更新版)[J]. 中国介入心脏病学杂志,2020,28(6):301-309.
[21] Hindricks GPotpara T,Dagres N,et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)[J]. Eur Heart J,2021,42(5):373-498.
[22] Nijenhuis VJ,Brouwer J,S?ndergaard L,et al. Antithrombotic therapy in patients undergoing transcatheter aortic valve implantation[J]. Heart,2019,105(10):742-748.
[23] Butt JH,de Backer O,Olesen JB,et al. Vitamin K antagonists vs. direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation[J]. Eur Heart J Cardiovasc Pharmacother,2021,7(1):11-19.
[24] Jochheim D,Barbanti M,Capretti G,et al. Oral anticoagulant type and outcomes after transcatheter aortic valve replacement[J]. JACC Cardiovasc Interv,2019,12(16):1566-1576.
[25] Collet JP,Berti S,Cequier A,et al. Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis:the randomized ATLANTIS trial[J]. Am Heart J,2018,200:44-50.
[26]Collet JP,van Belle E,Thiele H,et al. ATLANTIS:anti-thrombotic strategy to lower all cardiovascular and neurologic ischemic and hemorrhagic events after transaortic valve implantation for aortic stenosis:a randomized,open-label,phase 3 trial[EB/OL].https://www.acc.org/latest-in-cardiology/articles/2021/05/18/11/41/accel-lite-2021may18-acc-2021.
[27] Kawashima H,Watanabe Y,Hioki H,et al. Direct oral anticoagulants versus vitamin k antagonists in patients with atrial fibrillation after TAVR[J]. JACC Cardiovasc Interv,2020,13(22):2587-2597.
[28] van Mieghem NM,Unverdorben M,Valgimigli M,et al. Edoxaban versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation-Rationale and design of the ENVISAGE-TAVI AF trial[J]. Am Heart J,2018,205:63-69.
[29] Abdul-Jawad Altisent O,Durand E,Mu?oz-García AJ,et al. Warfarin and antiplatelet therapy versus?warfarin alone for treating patients?with?atrial fibrillation undergoing transcatheter aortic valve replacement[J]. JACC Cardiovasc Interv,2016,9(16):1706-1717.
[30] Geis NA,Kiriakou C,Chorianopoulos E,et al. Feasibility and safety of vitamin K antagonist monotherapy in atrial fibrillation patients undergoing transcatheter aortic valve implantation[J]. EuroIntervention,2017,12(17):2058-2066.
[31] Nijenhuis VJ,Brouwer J,Delewi R,et al. Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation[J]. N Engl J Med,2020,382(18):1696-1707.
[32] Kotronias RA,Kwok CS,George S,et al. Transcatheter aortic valve implantation with or without percutaneous coronary artery revascularization strategy:a systematic review and meta-analysis[J]. J Am Heart Assoc,2017,6(6):1-28.
[33] Goel SS,Ige M,Tuzcu EM,et al. Severe aortic stenosis and coronary artery disease--implications for management in the transcatheter aortic valve replacement era: a comprehensive review[J]. J Am Coll Cardiol,2013,62(1):1-10.
[34] Valgimigli M,Bueno H,Byrne RA,et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)[J]. Eur Heart J,2018,39(3):213-260.
[35] Osmancik P,Herman D,Neuzil P,et al. Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation[J]. J Am Coll Cardiol,2020,75(25):3122-3135.
[36] Reddy VY,Doshi SK,Kar S,et al. 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials[J]. J Am Coll Cardiol,2017,70(24):2964-2975.
[37] Zweiker D,Sieghartsleitner R,Fiedler L,et al. Indications and outcome in patients undergoing left atrial appendage closure-the Austrian LAAC registry[J]. J Clin Med,2020,9(10):1-14
[38] Attinger-Toller A,Maisano F,Senn O,et al. "one-stop shop": safety of combining transcatheter aortic valve replacement?and left atrial appendage occlusion[J]. JACC Cardiovasc Interv,2016,9(14):1487-1495.
相似文献/References:
[1]于子凯 许海燕 刘庆荣 吴永健.合并常见疾病对经导管主动脉瓣置换术患者预后的影响[J].心血管病学进展,2019,(5):697.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.009]
YU Zikai,XU Haiyan,LIU Qingrong,et al.Influence of ommon Accompanied Diseases on Prognosis of Patients after Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2019,(10):697.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.009]
[2]王斯佳 王国兴.抗栓治疗后消化道出血的现状及抗栓策略[J].心血管病学进展,2020,(8):790.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.002]
WANG Sijia,WANG G uoxing.Current Characteristics and Anti-thrombotic Strategy of Gastrointestinal Hemorrhage after Anti-thrombotic Therapy[J].Advances in Cardiovascular Diseases,2020,(10):790.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.002]
[3]邵美华 周玉强 王萌萌 王宝珠 马翔.经导管主动脉瓣置换术治疗二叶式主动脉瓣狭窄研究进展[J].心血管病学进展,2020,(11):1184.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
[4]刘新民 宋光远 吴永健.左心室导丝起搏技术在经导管主动脉瓣置换术中的应用[J].心血管病学进展,2021,(4):289.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.001]
LIU Xinmin,SONG Guangyuan,WU Yongjian.Application of Left Ventricular Guidewire Pacing in Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2021,(10):289.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.001]
[5]陈阳 赵庆豪 赵杰 吴永健.经导管主动脉瓣置换术时代慢性主动脉瓣反流诊治进展[J].心血管病学进展,2022,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.001]
CHEN Yang,ZHAO Qinghao,SONG Guangyuan,et al.Diagnosis and Treatment of Chronic Aortic Regurgitation in Transcatheter Aortic Valve Replacement Era[J].Advances in Cardiovascular Diseases,2022,(10):1.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.001]
[6]索妮 杨艳敏.心房颤动合并慢性冠状动脉综合征的抗栓治疗进展[J].心血管病学进展,2022,(1):30.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.008]
SUO Ni,Y ANG Yanmin.Antithrombotic Therapy for Atrial Fibrillation Complicated with Chronic Coronary Syndrome[J].Advances in Cardiovascular Diseases,2022,(10):30.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.008]
[7]董一娜 雷芳芳 宋启煦 王晶 杨艳.经导管主动脉瓣置换术后死亡风险预测模型系统评价[J].心血管病学进展,2022,(1):76.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.020]
DONG Yina,LEI Fangfang,SONG Qixu,et al.Mortality Risk Prediction Models After Transcatheter?span>Aortic Valve Replacement:A Systematic Review[J].Advances in Cardiovascular Diseases,2022,(10):76.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.020]
[8]王卫卫 于子凯 吴永健 许海燕 刘庆荣.序贯综合心脏康复模式在经导管主动脉瓣置换术患者中应用现状[J].心血管病学进展,2022,(8):673.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.001]
WANG Weiwei,YU Zikai,WU YongjianXU HaiyanLIU Qingrong.The Status of Sequential Comprehensive Cardiac Rehabilitation in Patients?ndergoing Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2022,(10):673.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.001]
[9]张航 安景辉 石凤梧.极简式经导管主动脉瓣置换术的研究现状[J].心血管病学进展,2022,(9):812.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.011]
ZHANG Hang,AN Jinghui,SHI Fengwu.Minimalist Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2022,(10):812.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.011]
[10]金冉阳 刘德敏 崔炜.经皮冠状动脉介入治疗围手术期抗栓治疗的演变[J].心血管病学进展,2023,(1):39.[doi:10.16806/j.cnki.issn.1004-3934.2023.01.010]
JIN Ranyang,LIU Demin,CUI Wei.Evolution of Antithrombotic Therapy During Perioperative PCI[J].Advances in Cardiovascular Diseases,2023,(10):39.[doi:10.16806/j.cnki.issn.1004-3934.2023.01.010]
[11]张木馨 李丽英 阮海燕 何森.经导管主动脉瓣置换术后抗栓治疗进展[J].心血管病学进展,2022,(6):518.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.010]
ZHANG Muxin,LI Liying,RUAN Haiyan,et al.Progress of Antithrombotic Therapy after?ranscatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2022,(10):518.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.010]
[12]. 经导管主动脉瓣置换术术后抗栓治疗的研究进展 [J].心血管病学进展,2022,(7):577.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
DUAN ZhenyaWU Yongjian.Antithrombotic Therapy After Transcatheter Aortic Valve Implantation[J].Advances in Cardiovascular Diseases,2022,(10):577.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]